title: Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma.
abstract: In vivo demonstration of hypoxia is of significance for tumour patient management. Fluorine-18 fluoromisonidazole ([18F]FMISO) is a proven hypoxic imaging agent. We developed an [18F]FMISO tumour to muscle retention ratio (TMRR) for the detection of tumour hypoxia in nasopharyngeal carcinoma (NPC). Data were acquired by positron emission tomography (PET) of the nasopharynx and neck after intravenous injection of 370 MBq of [18F]FMISO. Two imaging protocols were adopted: a long protocol for comprehensive dynamic information and a short protocol for a simple, clinically convenient imaging procedure. Tomograms were reconstructed and evaluated visually. ROI analysis on the basis of time-activity curve evaluation was performed to calculate the TMRR of NPC or cervical nodal metastases (CNMs) in relation to the suboccipital muscles at 2 h. The calculation of the TMRR was exactly the same for both the long and the short protocol as two 30-min composite frames had been created immediately after intravenous injection and 2 h after injection of [18F]FMISO in the long protocol. The normal tissue to muscle retention ratio (NTMRR) was derived similarly from the normal nasopharynx. The data of 12 controls and 24 patients with NPC were analysed. The long protocol was used in 15 patients, and the short protocol in nine. In controls, the mean NTMRR+/-1 SD was 0.96+/-0.14. The mean TMRRs for NPC and CNMs were 2.56+/-1.50 and 1.35+/-0.51, respectively; these values were significantly higher than the mean NTMRR for normal controls (P<0.005 in each case). At the retention threshold value of 1.24, tumour hypoxia occurred in 100% of the primary lesions of NPC and 58% of CNMs. The TMRR for undifferentiated carcinoma was significantly lower than that for non-keratinized carcinoma (P<0.05). The [18F]FMISO TMRR is a simple and clinically useful index for detecting tumour hypoxia in NPC.
authors.affiliation: National PET/Cyclotron Center and Department of Nuclear Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan.
authors.forename: S H
authors.initials: SH
authors.lastname: Yeh
authors.forename: R S
authors.initials: RS
authors.lastname: Liu
authors.forename: L C
authors.initials: LC
authors.lastname: Wu
authors.forename: D J
authors.initials: DJ
authors.lastname: Yang
authors.forename: S H
authors.initials: SH
authors.lastname: Yen
authors.forename: C W
authors.initials: CW
authors.lastname: Chang
authors.forename: T W
authors.initials: TW
authors.lastname: Yu
authors.forename: K L
authors.initials: KL
authors.lastname: Chou
authors.forename: K Y
authors.initials: KY
authors.lastname: Chen
mesh_terms: D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D016022:Case-Control Studies; D015687:Cell Hypoxia; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000031:analogs & derivatives*; D009303:Nasopharyngeal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D009305:Nasopharynx / Q000000981:diagnostic imaging; D009334:Neck Muscles / Q000000981:diagnostic imaging; D011838:Radiation-Sensitizing Agents; D014055:Tomography, Emission-Computed
chemical_list: D005462:Fluorine Radioisotopes; D011838:Radiation-Sensitizing Agents; C031843:fluoromisonidazole; D008920:Misonidazole